232 related articles for article (PubMed ID: 16242071)
1. Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Wemmert S; Ketter R; Rahnenführer J; Beerenwinkel N; Strowitzki M; Feiden W; Hartmann C; Lengauer T; Stockhammer F; Zang KD; Meese E; Steudel WI; von Deimling A; Urbschat S
Neoplasia; 2005 Oct; 7(10):883-93. PubMed ID: 16242071
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
3. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity on chromosomes 10q, 9p, 17p and 13q in malays with malignant glioma.
Zainuddin N; Jaafart H; Isa MN; Abdullah JM
Neurol Res; 2004 Jan; 26(1):88-92. PubMed ID: 14977064
[TBL] [Abstract][Full Text] [Related]
6. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
7. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.
Houillier C; Mokhtari K; Carpentier C; Crinière E; Marie Y; Rousseau A; Kaloshi G; Dehais C; Laffaire J; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
Neuro Oncol; 2010 Jan; 12(1):2-6. PubMed ID: 20150361
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
[TBL] [Abstract][Full Text] [Related]
12. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
14. High-grade glioma in children and adolescents: a single-center experience.
Yazici G; Zorlu F; Cengiz M; Ozyigit G; Eren G; Yüce D; Varan A; Akyuz C; Akalan N; Gurkaynak M
Childs Nerv Syst; 2016 Feb; 32(2):291-7. PubMed ID: 26679932
[TBL] [Abstract][Full Text] [Related]
15. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
16. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA;
J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
20. Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Li XM; Lin W; Wang J; Zhang W; Yin AA; Huang Y; Zhang J; Yao L; Bian H; Zhang J; Zhang X
Mol Med Rep; 2016 Dec; 14(6):5626-5636. PubMed ID: 27840944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]